Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 3/20 | 0.39 |
| ▸ | TTK | P33981 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22125051 | 1.00 | PTK6 (0.39) | PTK6TTKKDM4EGAASMN1; SMN2 | |
| SCHEMBL22123059 | 0.93 | PTK6 (0.39) | PTK6TTKKDM4EGAASMN1; SMN2 | |
| SCHEMBL24112523 | 0.92 | PTK6 (0.41) | PTK6TTKKDM4EGAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL25176396 | 0.92 | PTK6 (0.39) | PTK6TTKKDM4EGAASMN1; SMN2 | |
| SCHEMBL25450711 | 0.91 | PTK6 (0.38) | PTK6TTKKDM4EGAASMN1; SMN2 | |
| SCHEMBL30385702 | 0.90 | BRD4 (0.40) | PTK6TTKKDM4EGAASMN1; SMN2 | |
| SCHEMBL22122840 | 0.89 | KDM4E (0.42) | PTK6TTKKDM4EGAASMN1; SMN2 | |
| SCHEMBL24940112 | 0.89 | PTK6 (0.39) | PTK6TTKBRAFMAPKAPK5LCK | |
| Formic Acid SCHEMBL25170401 | 0.88 | PTK6 (0.36) | PTK6TTKKDM4EGAASMN1; SMN2 | |
| SCHEMBL25014260 | 0.88 | PTK6 (0.35) | PTK6TTKMAPKAPK5IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2141/4885TTK 4573/4885KDM4E 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.